Valuation: Damora Therapeutics, Inc.

Market Cap 1.94B 1.69B 1.56B 1.44B 2.71B 187B 2.77B 18.68B 7.35B 91.39B 7.28B 7.12B 315B P/E 2026 *
-16.5x
P/E 2027 * -15.2x
Enterprise Value 1.49B 1.31B 1.21B 1.11B 2.09B 144B 2.14B 14.41B 5.67B 70.51B 5.61B 5.49B 243B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.38%
Yield 2026 *
-
Yield 2027 * -
1 day+4.10%
1 week+10.34%
Current month+21.03%
1 month+48.28%
3 months+18.35%
6 months+26.05%
Current year+36.81%
1 week 26.29
Extreme 26.29
31.87
1 month 21.51
Extreme 21.51
31.87
Current year 16.5
Extreme 16.5001
33.99
1 year 2.45
Extreme 2.45
38.33
3 years 2.01
Extreme 2.01
92.5
5 years 2.01
Extreme 2.01
118.75
10 years 2.01
Extreme 2.01
449.75
Manager TitleAgeSince
Chief Executive Officer 55 29/03/2026
Director of Finance/CFO - 30/04/2026
Chief Tech/Sci/R&D Officer 60 04/01/2026
Director TitleAgeSince
Chairman 40 22/03/2026
Director/Board Member 42 09/11/2025
Director/Board Member 41 09/11/2025
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Sell

General Counsel

-245 0.0004%
01/05/26 Other

Chief Financial Officer

312,535 0.5077%
30/03/26 Free

Chief Executive Officer

2,000,000 3.3200%
Change 5-day change 1-year change 3-year change Capi.($)
+4.10%+10.34%+777.69%-47.97% 1.94B
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.08%-1.33%+114.26%+160.84% 23.55B
Weighted average by Cap. -2.74%-2.25%+45.62%+141.55%

Financials

2026 *2027 *
Net sales - -
Net income -117M -102M -94.15M -86.79M -164M -11.24B -167M -1.13B -443M -5.51B -438M -429M -18.96B -144M -126M -116M -107M -202M -13.9B -207M -1.39B -547M -6.81B -542M -530M -23.43B
Net Debt -443M -387M -357M -329M -620M -42.64B -634M -4.27B -1.68B -20.88B -1.66B -1.63B -71.89B -326M -285M -263M -243M -457M -31.43B -467M -3.15B -1.24B -15.39B -1.23B -1.2B -53B
Logo Damora Therapeutics, Inc.
Damora Therapeutics Inc, formerly Galecto, Inc, is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company is engaged in the advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. It offers a multiple programs including asset, DMR-001, an investigational monoclonal antibody therapy targeting mutCALR. DMR-001 was designed to exclusively bind to mutCALR with exquisite selectivity, potency, and extended half-life, with potential to enable convenient, infrequent subcutaneous dosing.
Employees
7
Date Price Change Volume
17/07/26 US$31.48 +4.10% 489,023
16/07/26 US$30.24 -2.29% 356,045
15/07/26 US$30.95 -0.13% 622,554
14/07/26 US$30.99 +10.68% 528,478
13/07/26 US$28.00 -1.86% 269,786
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
31.48USD
Average target price
43.38USD
Spread / Average Target
+37.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMRA Stock